Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells.

被引：0
|
作者：
Yu, Seo Young [1 ]
Park, Juin [2 ]
Kwon, Woo Sun [2 ]
Jeong, Inhye [2 ]
Kang, Sun Kyoung [2 ]
Bae, Hyun Joo [1 ]
Kim, Tae Soo [2 ]
Chung, Hyun Cheol [3 ]
Rha, Sun Young [3 ]
机构：
[1] Yonsei Univ, Coll Med, Brain Korea 21 PLUS Project Med Sci, Seoul, South Korea
[2] Yonsei Univ, Songdang Inst Canc Res, Coll Med, Seoul, South Korea
[3] Yonsei Univ Hlth Syst, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
945
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Impact of HER2 Expression on trastuzumab deruxtecan(T-DXd) efficacy
    Chen, Wanyi
    Drago, Joshua
    Gupta, Avantika
    Liu, Bo
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Overcoming trastuzumab resistance using trastuzumab deruxtecan (T-DXd), a HER2 targeting antibody drug conjugate, in HER2 amplified gastric cancer.
    Park, Juin
    Jeong, Inhye
    Kang, Sun Kyoung
    Yu, Seo Young
    Kwon, Woo Sun
    Kim, Tae Soo
    Hwang, Jihyun
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2021, 81 (13)
  • [3] IN VITRO AND IN VIVO EFFICACY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN EPITHELIAL OVARIAN CANCER WITH HER2/NEU OVEREXPRESSION
    Mutlu, Levent
    Manavella, Diego
    Bellone, Stefania
    Santin, Alessandro
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A54 - A54
  • [4] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [5] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
    Nozawa, Kazuki
    Kusudo, Maho
    Kureyama, Nari
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
    Tarantino, P.
    Kim, S. E.
    Chan, N. N. N.
    Hughes, M. E.
    Smith, K.
    D'Amico, O. R.
    Kusmick, R.
    Pereslete, A. M.
    Alder, L.
    Anders, C.
    Morganti, S.
    Garrido-Castro, A. C.
    Lorusso, P.
    Lustberg, M.
    Sammons, S.
    Lin, N.
    Li, T.
    Tayob, N.
    Rimm, D.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S384 - S385
  • [7] PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Hennig, S.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S93 - S94
  • [8] HER2 expression-independent antitumor effect of trastuzumab deruxtecan (T-DXd) on pediatric solid tumors
    Takasugi, Nao
    Deguchi, Takao
    Kato, Motohiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Wei, T.
    Wang, D.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 948 - 949
  • [10] Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
    Andrikopoulou, Angeliki
    Zagouri, Flora
    Goula, Kallirroi
    Haidopoulos, Dimitrios
    Thomakos, Nikolaos
    Svarna, Anna
    Dimopoulos, Meletios-Athanasios
    Liontos, Michalis
    BMC CANCER, 2024, 24 (01)
12345